• Vivesto received FDA orphan drug designation for Cantrixil to treat acute myeloid leukemia, supporting its development toward a Phase I trial.
• The designation offers potential development incentives, including clinical trial tax credits, with possible seven-year U.S. market exclusivity following marketing approval.
• Previously reported preclinical results showed anticancer activity, both alone and with established treatments; Cantrixil remains in preclinical development for AML.
• An earlier Phase I trial evaluated Cantrixil in ovarian cancer; the AML trial is planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivesto AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.